As of 4 December 2023 we are able to offer the new Monovalent Omicron XBB.1.5 vaccine.
All currently available COVID-19 vaccines are anticipated to provide benefit to eligible people, however the monovalent Omicron XBB.1.5 vaccines are preferred over other vaccines for the use in children aged 5 years or older and adults who are currently recommended primary or additional doses of COVID-19 vaccine.
A 2023 COVID-19 vaccine dose is recommended for the following groups, to be given at least 6 months after their most recent COVID-19 vaccine dose/infection:
- All adults aged ≥65 years,
- adults aged 18 - <65 years who have medical comorbidities that increase their risk of severe COVID-19, and
- adults who have a disability with significant or complex health needs.
A 2023 dose may be considered for other adults aged 18 - <65 years, based on an individual risk-benefit assessment.
A second 2023 COVID-19 vaccine dose, is recommended for all adults aged ≥75 years if 6 months have passed since their last dose.
People who become eligible for 2023 doses should continue to receive these doses until updated advice becomes available in early 2024.
For those who have had the recommended 2023 dose/s of COVID-19 vaccine, ATAGI is not recommending further doses or re-vaccination with an XBB.1.5-containing vaccine at this time.
There are no monovalent XBB.1.5-containing vaccines registered for use in children aged 6 months to 4 years.
Book an appointment online via our website or call us to book. Please note stock will not be received until 4 December 2023.